This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andes, D.
Right arrow Articles by Conklin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andes, D.
Right arrow Articles by Conklin, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 922-926, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.922-926.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis Model

D. Andes,1,* T. Stamsted,2 and R. Conklin2

Section of Infectious Diseases, Department of Medicine, University of Wisconsin School of Medicine,1 and Section of Clinical Pharmacology, Department of Medicine, William S. Middleton VA Hospital,2 Madison, Wisconsin

Received 13 June 2000/Returned for modification 21 October 2000/Accepted 27 November 2000

In vivo pharmacodynamic parameters have been described for a variety of antibacterials. These parameters have been studied in correlation with in vivo outcomes in order to determine which dosing parameter is predictive of outcome and the magnitude of that parameter associated with efficacy. Very little is known about pharmacodynamics for antifungal agents. We utilized a neutropenic mouse model of disseminated candidiasis to correlate pharmacodynamic parameters (percent time above MIC [T > MIC], area under the concentration time curve [AUC]/MIC ratio, and peak serum level/MIC ratio) for amphotericin B in vivo with efficacy, as measured by organism number in homogenized kidney cultures after 72 h of therapy. Amphotericin B was administered by the intraperitoneal route. Drug kinetics for amphotericin B in infected mice were nonlinear. Serum half-lives ranged from 13 to 27 h. Infection was achieved by intravenous inoculation with 106 CFU of yeast cells per ml via the lateral tail vein of neutropenic mice. Groups of mice were treated with fourfold escalating total doses of amphotericin B ranging from 0.08 to 20 mg/kg of body weight divided into 1, 3, or 6 doses over 72 h. Increasing doses produced concentration-dependent killing, ranging from 0 to 2 log10 CFU/kidney compared to the organism number at the start of therapy. Amphotericin B also produced prolonged dose-dependent suppression of growth after serum levels had fallen below the MIC. Nonlinear regression analysis was used to determine which pharmacodynamic parameter best correlated with efficacy. Peak serum level in relation to the MIC (peak serum level/MIC ratio) was the parameter best predictive of outcome, while the AUC/MIC ratio and T > MIC were only slightly less predictive (peak serum level/MIC ratio, coefficient of determination [R2] = 90 to 93%; AUC/MIC ratio, R2 = 49 to 69%; T > MIC, R2 = 67 to 85%). The total amount of drug necessary to achieve various microbiological outcomes over the treatment period was 4.8- to 7.6-fold smaller when the dosing schedule called for large single doses than when the same amount of total drug was administered in 2 to 6 doses. Given the narrow therapeutic window of amphotericin B and frequent treatment failures, these results suggest the need for a reevaluation of current dosing regimens.

* Corresponding author. Mailing address: Section of Infectious Diseases, Department of Medicine, University of Wisconsin School of Medicine, Room H4/570, 600 Highland Ave., Madison, WI 53792. Phone: (608) 263-1545. Fax: (608) 263-4464. E-mail: drandes{at}facstaff.wisc.edu.

Antimicrobial Agents and Chemotherapy, March 2001, p. 922-926, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.922-926.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gubbins, P. O., Amsden, J. R., McConnell, S. A., Anaissie, E. J. (2009). Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients. Antimicrob. Agents Chemother. 53: 3664-3674 [Abstract] [Full Text]  
  • Andes, D., Pascual, A., Marchetti, O. (2009). Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrob. Agents Chemother. 53: 24-34 [Full Text]  
  • Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J. (2008). In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 3497-3503 [Abstract] [Full Text]  
  • Lignell, A., Lowdin, E., Cars, O., Sjolin, J. (2008). Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model. J Antimicrob Chemother 62: 142-148 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]  
  • Goodwin, M. L., Drew, R. H. (2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61: 17-25 [Abstract] [Full Text]  
  • Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., Walsh, T. J., Denning, D. W., Drusano, G. L. (2007). Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing. Antimicrob. Agents Chemother. 51: 3760-3762 [Abstract] [Full Text]  
  • Smith, P. J., Olson, J. A., Constable, D., Schwartz, J., Proffitt, R. T., Adler-Moore, J. P. (2007). Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 59: 941-951 [Abstract] [Full Text]  
  • Lepak, A., Nett, J., Lincoln, L., Marchillo, K., Andes, D. (2006). Time Course of Microbiologic Outcome and Gene Expression in Candida albicans during and following In Vitro and In Vivo Exposure to Fluconazole.. Antimicrob. Agents Chemother. 50: 1311-1319 [Abstract] [Full Text]  
  • Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y. (2006). Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 57: 724-731 [Abstract] [Full Text]  
  • Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., McLachlan, A. J. (2006). Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases. Antimicrob. Agents Chemother. 50: 935-942 [Abstract] [Full Text]  
  • Wiederhold, N. P., Tam, V. H., Chi, J., Prince, R. A., Kontoyiannis, D. P., Lewis, R. E. (2006). Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 50: 469-473 [Abstract] [Full Text]  
  • Andes, D., Safdar, N., Marchillo, K., Conklin, R. (2006). Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models. Antimicrob. Agents Chemother. 50: 674-684 [Abstract] [Full Text]  
  • Lewis, R. E., Wiederhold, N. P., Prince, R. A., Kontoyiannis, D. P. (2006). In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J Antimicrob Chemother 57: 288-293 [Abstract] [Full Text]  
  • Cacciapuoti, A., Gurnani, M., Halpern, J., Norris, C., Patel, R., Loebenberg, D. (2005). Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In Vivo. Antimicrob. Agents Chemother. 49: 638-642 [Abstract] [Full Text]  
  • Kontoyiannis, D. P., Lewis, R. E., Tattevin, P., Bareau, B., Camus, C., Marty, F. M., Lowry, C. M., Schneemann, M., Imhof, A., Danaher, P. J., Jones, B. L., McLintock, L. A., Walsh, T. J., Donowitz, G. R., dePauw, B. E. (2005). Caspofungin versus liposomal amphotericin B for empirical therapy.. NEJM 352: 410-414 [Full Text]  
  • Chryssanthou, E., Sjolin, J. (2004). Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration. J Antimicrob Chemother 54: 940-943 [Abstract] [Full Text]  
  • Takemoto, K., Yamamoto, Y., Ueda, Y., Sumita, Y., Yoshida, K., Niki, Y. (2004). Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother 53: 311-317 [Abstract] [Full Text]  
  • Vitale, R. G., Meis, J. F. G. M., Mouton, J. W., Verweij, P. E. (2003). Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. J Antimicrob Chemother 52: 65-70 [Abstract] [Full Text]  
  • Andes, D. (2003). In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrob. Agents Chemother. 47: 1179-1186 [Full Text]  
  • Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 1187-1192 [Abstract] [Full Text]  
  • Lewis, R. E., Prince, R. A., Chi, J., Kontoyiannis, D. P. (2002). Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 46: 3208-3214 [Abstract] [Full Text]  
  • Vitale, R. G., Mouton, J. W., Afeltra, J., Meis, J. F. G. M., Verweij, P. E. (2002). Method for Measuring Postantifungal Effect in Aspergillus Species. Antimicrob. Agents Chemother. 46: 1960-1965 [Abstract] [Full Text]  
  • Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W. (2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev. 14: 643-658 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»